Linked Life Data

8336653

Source:http://linkedlifedata.com/resource/pubmed/id/8336653

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1993-8-24
pubmed:abstractText
Mebendasole is better absorbed in the gastrointestinal tract if administered together with essential to patients with hydatid disease. Thirty-four patients with alveolar and hydatid echinococcosis were administered mebendasol in a daily dose of 50 mg/kg in 4 doses and essentiale in a daily dose of 600-1000 mg in 4 doses. A total of 86 therapeutic courses, 30 days each, were carried out. The treatment was sufficiently well tolerated. Mebendasole levels in the course of therapy surpassed the minimal effective ones in 2/3 of the patients, that is, they were significantly higher than in administration of mebendasole alone.
pubmed:language
rus
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0025-8326
pubmed:author
pubmed:issnType
Print
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
43-5
pubmed:dateRevised
2009-10-21
pubmed:meshHeading
pubmed:articleTitle
[The enhanced bioavailability of mebendazole in echinococcosis patients when used with Essentiale].
pubmed:publicationType
Journal Article, English Abstract